Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.8
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 16705182
Chang KA, et al. (2006) Phosphorylation of amyloid precursor protein (APP) at Thr668 regulates the nuclear translocation of the APP intracellular domain and induces neurodegeneration. Mol Cell Biol 26, 4327-38 16705182
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

T668-p - APP iso4 (human)
Modsite: VEVDAAVtPEERHLS SwissProt Entrez-Gene
Orthologous residues
APP (human): T743‑p, APP iso4 (human): T668‑p, APP iso8 (human): T724‑p, APP iso10 (human): T612‑p, APP (mouse): T743‑p, APP iso2 (mouse): T668‑p, APP (rat): T743‑p, APP iso2 (rat): T668‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  Alzheimer's disease, adrenal cancer, pheochromocytoma
Relevant cell lines - cell types - tissues:  'neuron, cortical'-brain, 'neuron, hippocampal'-brain, PC-12 (chromaffin)
Cellular systems studied:  cell lines, primary cells, tissue
Species studied:  human, mouse, rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
olomoucine decrease
seliciclib decrease
lithium decrease
Downstream Regulation
Effect of modification (function):  intracellular localization, molecular association, regulation, phosphorylation
Effect of modification (process):  apoptosis, altered, transcription, altered
Modification regulates interactions with: 
Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays
Fe65 (rat) Induces co-immunoprecipitation, FRET
TFCP2 (human) Induces co-immunoprecipitation
Comments:  regulates Tau and GSK3B phosphorylation
Associated Diseases
Diseases Alterations Comments
Alzheimer's disease increased

Y216-p - GSK3B (rat)
Modsite: RGEPNVsyICsRyYR SwissProt Entrez-Gene
Orthologous residues
GSK3B (human): Y216‑p, GSK3B iso2 (human): Y216‑p, GSK3B (mouse): Y216‑p, GSK3B (rat): Y216‑p, GSK3B (rabbit): Y216‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  Alzheimer's disease, adrenal cancer, pheochromocytoma
Relevant cell lines - cell types - tissues:  'neuron, cortical'-brain, 'neuron, hippocampal'-brain, PC-12 (chromaffin)
Cellular systems studied:  cell lines, primary cells, tissue
Species studied:  human, mouse, rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
APP (human) increase

S513-p - Tau (rat)
Modsite: SGyssPGsPGtPGsR SwissProt Entrez-Gene
Orthologous residues
Tau (human): S519‑p, Tau iso2 (human): S144‑p, Tau iso3 (human): S108‑p, Tau iso4 (human): S173‑p, Tau iso5 (human): S202‑p, Tau iso6 (human): S144‑p, Tau iso7 (human): S173‑p, Tau iso8 (human): S202‑p, Tau (mouse): S494‑p, Tau iso3 (mouse): S191‑p, Tau iso7 (mouse): S151‑p, Tau (rat): S513‑p, Tau (cow): S209‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  Alzheimer's disease, adrenal cancer, pheochromocytoma
Relevant cell lines - cell types - tissues:  'neuron, cortical'-brain, 'neuron, hippocampal'-brain, PC-12 (chromaffin)
Cellular systems studied:  cell lines, primary cells, tissue
Species studied:  human, mouse, rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
APP (human) increase
olomoucine decrease
seliciclib decrease
lithium decrease
Associated Diseases
Diseases Alterations Comments
Alzheimer's disease increased

T516-p - Tau (rat)
Modsite: ssPGsPGtPGsRSRt SwissProt Entrez-Gene
Orthologous residues
Tau (human): T522‑p, Tau iso2 (human): T147‑p, Tau iso3 (human): T111‑p, Tau iso4 (human): T176‑p, Tau iso5 (human): T205‑p, Tau iso6 (human): T147‑p, Tau iso7 (human): T176‑p, Tau iso8 (human): T205‑p, Tau (mouse): T497‑p, Tau iso3 (mouse): T194‑p, Tau iso7 (mouse): T154‑p, Tau (rat): T516‑p, Tau (cow): T212‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  Alzheimer's disease, adrenal cancer, pheochromocytoma
Relevant cell lines - cell types - tissues:  'neuron, cortical'-brain, 'neuron, hippocampal'-brain, PC-12 (chromaffin)
Cellular systems studied:  cell lines, primary cells, tissue
Species studied:  human, mouse, rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
APP (human) increase
olomoucine decrease
seliciclib decrease
lithium decrease
Associated Diseases
Diseases Alterations Comments
Alzheimer's disease increased